1) Strategy & Leadership
- STERIS is maintaining its original fiscal 2027 outlook, projecting as-reported revenue growth of 7%-8% and constant currency organic revenue growth of 6%-7%.
- The company announced a $600 million investment to build a new Formulated Chemistry Center of Excellence in North Carolina, aimed at enhancing manufacturing capabilities and supporting growth in high-margin products.
- The facility is expected to be operational in two to three years, with a phased approach to opening.

2) Financial & Segment Results
- Total revenue grew 7% YoY, with constant currency organic revenue growth of 6% driven by volume and pricing.
- Gross margin improved to 46%, up 70 basis points YoY, while EBIT margin increased to 23.8%, reflecting operational discipline and favorable currency effects.
- Adjusted net income was $253.4 million, with earnings per diluted share at $2.59, an 11% increase YoY.
- Free cash flow decreased to $279.6 million, down from $326.5 million in the prior year, primarily due to lower working capital contributions.

3) Operational Insights & Product Plans
- The Healthcare segment saw 6% constant currency organic revenue growth, with services growing 10% and consumables 9%.
- The Life Sciences group reported 8% organic revenue growth, driven by a 17% increase in capital equipment sales.
- The company is experiencing strong demand in endoscopy, with share gains noted in both equipment and consumables.
- A restructuring program is anticipated to incur $55 million-$70 million in pretax charges, with benefits expected from the new facility's consolidation and modernization.

4) Problems / Headwinds
- The AST segment faced challenges with 5% organic revenue growth, attributed to soft global demand and inventory destocking. EBIT margins decreased to 48%, impacted by increased depreciation and lower productivity.
- Tariff costs were $14 million, slightly higher than the previous year's $12 million, although net tariffs were favorable by $2 million due to refunds.

5) Guidance & Outlook / Investor Angle
- The company expects fiscal 2027 earnings per share to be in the range of $11.10-$11.30, reflecting 9%-11% growth over fiscal 2026.
- Free cash flow is projected to be $800 million, despite the additional capital spending related to the new facility.
- The investment in North Carolina is expected to generate a return on invested capital (ROIC) of over 10% within three to five years of opening.

Bottom line: STERIS is positioned for steady growth with a solid outlook for fiscal 2027, bolstered by strategic investments and strong performance in key segments, despite facing some operational headwinds in the AST segment.